Klingemann HG - Search Results

1

Hematopoietic stem cell transplantation: bone marrow vs. mobilized peripheral blood.

Arai S, Klingemann HG. Arai S, et al. Among authors: klingemann hg. Arch Med Res. 2003 Nov-Dec;34(6):545-53. doi: 10.1016/j.arcmed.2003.07.002. Arch Med Res. 2003. PMID: 14734094 Review.

2

Natural killer cells: can they be useful as adoptive immunotherapy for cancer?

Arai S, Klingemann HG. Arai S, et al. Among authors: klingemann hg. Expert Opin Biol Ther. 2005 Feb;5(2):163-72. doi: 10.1517/14712598.5.2.163. Expert Opin Biol Ther. 2005. PMID: 15757378 Review.

3

Mini-transplants turning micro: how low can we go?

Klingemann HG. Klingemann HG. J Hematother Stem Cell Res. 2002 Dec;11(6):859-62. doi: 10.1089/152581602321080510. J Hematother Stem Cell Res. 2002. PMID: 12590700 Review. No abstract available.

4

The foundations of cellular therapy: Barnes and Loutit, 1957.

English D, Klingemann HG. English D, et al. Among authors: klingemann hg. J Hematother Stem Cell Res. 2001 Jun;10(3):323-4. doi: 10.1089/152581601750288911. J Hematother Stem Cell Res. 2001. PMID: 11454306 No abstract available.

5

Immunotherapy with dendritic cells: coming of age?

Klingemann HG. Klingemann HG. J Hematother Stem Cell Res. 2000 Apr;9(2):127-8. doi: 10.1089/152581600319324. J Hematother Stem Cell Res. 2000. PMID: 10813524 No abstract available.

6

STI-stop transplanting immediately?

Klingemann HG. Klingemann HG. J Hematother Stem Cell Res. 2002 Apr;11(2):165-7. doi: 10.1089/152581602753658367. J Hematother Stem Cell Res. 2002. PMID: 11983089 No abstract available.

7

Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.

Xu X, Rao G, Gaffud MJ, Ding HG, Maki G, Klingemann HG, Groh V, Spies T, Caillat-Zucman S, Gattuso P, Plate J, Prinz RA. Xu X, et al. Among authors: klingemann hg. J Clin Endocrinol Metab. 2006 Jul;91(7):2704-12. doi: 10.1210/jc.2006-0492. Epub 2006 Apr 18. J Clin Endocrinol Metab. 2006. PMID: 16621903

8

Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments.

Delcommenne M, Klingemann HG. Delcommenne M, et al. Among authors: klingemann hg. Hum Antibodies. 2012;21(1-2):29-40. doi: 10.3233/HAB-2012-0259. Hum Antibodies. 2012. PMID: 22885958

9

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.

Eitler J, Wotschel N, Miller N, Boissel L, Klingemann HG, Wels W, Tonn T. Eitler J, et al. Among authors: klingemann hg. J Immunother Cancer. 2021 Jan;9(1):e001334. doi: 10.1136/jitc-2020-001334. J Immunother Cancer. 2021. PMID: 33468562 Free PMC article.

10

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. Suck G, et al. Among authors: klingemann hg. Cancer Immunol Immunother. 2016 Apr;65(4):485-92. doi: 10.1007/s00262-015-1761-x. Epub 2015 Nov 11. Cancer Immunol Immunother. 2016. PMID: 26559813 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page